<DOC>
	<DOCNO>NCT02847377</DOCNO>
	<brief_summary>The development biomarkers lead dynamic personalized medicine fill unsatisfied need oncology prediction therapeutic response . Molecular imaging enables non invasive quantification biomarkers . The development molecular imaging biomarkers closely related development therapeutic molecule . Among potential target , kinase offer lot advantage : ( ) play central role cellular regulation , ( ii ) numerous kinase-specific small molecule library exist biotech pharma industry , ( iii ) several kinase-targeted therapy use clinic ( imatinib , sorafenib , sunitinib… ) application across variety therapeutic indication . Among image technology , Positron Emission Tomography ( PET ) sensitive dedicate evaluate small molecule . However radiotracers available specificity limit clinical use . The IMAkinib® approach innovative method propose develop new PET radiotracers adapt current medical economical challenge . The epidermal growth factor receptor ( EGFR ) establish target treatment advance non-small cell lung cancer ( NSCLC ) . The EGFR tyrosine kinase inhibitor ( TKIs ) Gefitinib ( Iressa® ) , erlotinib ( Tarceva® ) afatinib ( Giotrif® ) already approve treatment NSCLC harbor EGFR activate mutation ( L858R del exon 19 ) . Unfortunately majority patient develop resistance TKI long term ( 6-12 month ) . If mechanism resistance yet fully characterize , patient ( 50 % ) acquire additional T790M mutation EGFR . TKI PET-imaging provide tool determine predict responsiveness EGFR TKI vivo . That , investigator select radiolabeled ( 18-Fluor ) compound target specifically EGFR mutate ( [ 18F ] -ODS2004436 ) evaluate preclinical imaging study determine feasibility TKI-PET . The investigator prove vivo [ 18F ] -ODS2004436 compound good candidate evaluate EGFR activity human lung tumour use PET imaging .</brief_summary>
	<brief_title>A Positron Emission Tomography ( PET ) Imaging Agent 18F-ODS2004436 Marker EGFR Mutation Subjects With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>18 year , Willing able sign write informed consent , Histologically confirm diagnosis adenocarcinoma NSCLC : 1. positive mutate KRas homogeneous population EGFR Wild type ( WT ) patient ( exclusive EGFR mutation ) 2 . EGFR activate mutation ( All mutation : 719 , 790 , 861 , 858 del exon 19 exon 20 ) , Patient EGFR mutation sensitive TKI Treatment naïve patient , Performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) criterion , No concomitant prescription include cyclosporin A , valproic acid , phenobarbital , phenytoin , ketoconazole , Adequate hematologic ( ANC count ≥ 1,500/uL , platelet count ≥ 100,000/mm3 ) , hepatic ( bilirubin level ≤ 1.5 mg/dL , Transaminase ( AST/ALT ) ≤ 80 IU/L ) , renal ( creatinine concentration ≤ 1.5 mg/dL ) function , Patients brain metastasis allow unless clinically significant neurological symptom sign . Known severe hypersensitivity Gefitinib Afatinib tablet excipients , Inability swallow tablet , Other coexist malignant disease , Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's wort ; severe uncontrolled systemic disease ; clinically active interstitial lung disease ( except uncomplicated lymphangitic carcinomatosis ) , Female subject pregnant , breastfeed male female patient reproductive potential employ effective method birth control , Subjects guardianship , curator judicial protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>